Progressive supranuclear palsy (PSP), previously believed to be a common cause of
atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes …

Background Aside from idiopathic Parkinson syndrome (Parkinson's disease), there are a
number of other, so-called atypical parkinsonian syndromes: dementia with Lewy bodies …

Dopamine is an important neurotransmitter implicated in the regulation of mood, motivation
and movement. We have reviewed here recent data suggesting that dopamine, in addition to …

Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

Cerebral dopamine depletion is the hallmark of Parkinson disease. Because dopamine
modulates ontogenetic neurogenesis, depletion of dopamine might affect neural precursors …

Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau
neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most …

In Parkinson's disease, nigral dopaminergic neurones degenerate, whereas post‐synaptic
striatal target neurones are spared. In some atypical parkinsonian syndromes, both nigral …

Progressive supranuclear palsy (PSP) is a 4R-tauopathy predominated by subcortical
pathology in neurons, astrocytes, and oligodendroglia associated with various clinical …

In multiple sclerosis (MS), oligodendrocyte and myelin destruction lead to demyelination
with subsequent axonal loss. Experimental demyelination in rodents has highlighted the …

The phenotypic variability of progressive supranuclear palsy (PSP) may account for its
frequent misdiagnosis, in particular in early stages of the disease. However, large …